From: Policy relevant results from an expert elicitation on the health risks of phthalates
a) The questions with consensus (CNS) outside the 10-90 percentile range. | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Question | VL | L | M | H | VH | No. Resp | Mean | STD | CNS | Rank (CNS) |
Exposure | 1 | 2 | 3 | 4 | 5 | |||||
Levels of exposure in the general population | 0 | 4 | 10 | 1 | 0 | 15 | 2,80 | 0,56 | 0,83 | 3 |
Levels of oral exposure, general population | 0 | 1 | 4 | 0 | 0 | 5 | 2,80 | 0,45 | 0,88 | 1 |
Human body | ||||||||||
Adverse health effects in humans | 0 | 3 | 9 | 3 | 0 | 15 | 3,00 | 0,65 | 0,83 | 2 |
Adverse health effects in male experimental animals | 2 | 5 | 3 | 4 | 1 | 15 | 2,80 | 1,21 | 0,55 | 32 |
Mechanisms of action of phtalates | 1 | 2 | 0 | 8 | 4 | 15 | 3,80 | 1,21 | 0,59 | 30 |
Mechanisms of action of phtalate metabolites | 3 | 2 | 5 | 4 | 1 | 15 | 2,87 | 1,25 | 0,55 | 31 |
b) The questions with an average confidence score (Mean) outside the 10-90 percentile range | ||||||||||
Questions | VL | L | M | H | VH | No. Resp | Mean | STD | CNS | Rank (CNS) |
Source | 1 | 2 | 3 | 4 | 5 | |||||
Annual production volumes of phthalates | 0 | 1 | 6 | 5 | 3 | 15 | 3,67 | 0,90 | 0,68 | 16 |
Exposure | ||||||||||
Levels of oral exposure, highly exposed groups | 0 | 0 | 2 | 3 | 0 | 5 | 3,60 | 0,55 | 0,82 | 4 |
Levels of dermal exposure, general population | 0 | 3 | 2 | 0 | 0 | 5 | 2,40 | 0,55 | 0,82 | 5 |
Human body | ||||||||||
Final concentration in target tissues | 3 | 3 | 4 | 1 | 0 | 11 | 2,27 | 1,01 | 0,64 | 22 |
Differences in toxicokinetics, identifying sensitive groups | 2 | 5 | 3 | 0 | 1 | 11 | 2,36 | 1,12 | 0,62 | 26 |
Mechanisms of action of phthalates | 1 | 2 | 0 | 8 | 4 | 15 | 3,80 | 1,21 | 0,59 | 30 |
Ability to cause endocrine disruption in the metabolic system | 4 | 2 | 8 | 1 | 0 | 15 | 2,40 | 0,99 | 0,64 | 23 |